Comparison of therapy response in patients given rpFVIII as first-line vs second-line therapy as previously defined. When used as second-line therapy, more cumulative rpFVIII was required for bleed control in our cohort (see “Results” and “Discussion” for details). Median dose required for the second-line dosing was 1400 U/kg, and was, for upfront dosing, 300 U/kg with a P value of .0016 by Mann-Whitney U test. (A) Cumulative rpFVIII dose required for presenting bleed. (B) Preexposure pBIA in first-line and second-line groups. There was no significant difference in preexposure pBIA between those treated with rpFVIII as first line or second line by the same test.